![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Pfizer Announces FDA Will No Longer Require Warning Label for Its Chantix Medication
Pfizer Announces FDA Will No Longer Require Warning Label for Its Chantix Medication
December 23, 2016
Pfizer announced that the FDA will no longer require the company’s smoking-cessation pill Chantix to carry a warning about a potential link to suicide, depression and hostile behavior.
In addition, the label can now also state that Chantix works better than the nicotine patch and a generic smoking-cessation pill known as bupropion.
The FDA made its decision based on results from an 8,144-subject study probing the safety of Chantix and bupropion, sponsored by Pfizer and GlaxoSmithKline. The study found results from an 8,144-subject study probing the safety of Chantix and bupropion, sponsored by Pfizer and GlaxoSmithKline.
Upcoming Events
-
21Oct